Navigation Links
Measurement Challenges In Detecting Cancer Biomarkers

Effective control of sexually transmitted diseases (STDs) requires treatment of the sexual partners of infected patients. A new study shows that providing infected men with antibiotics to give their partners is more effective than traditional means of contacting and treating the partners, according to an article in the Sept. 1 issue of Clinical Infectious Diseases, now available online. Men with chlamydia or gonorrhea were more likely to see and talk to their female partners about the STD when given medicine to give to their partners than the men who were simply told to inform their partners of their STD exposure.

Partner referral is the most common method of attempting to control STD spread and recurrence. Health care providers ask STD-infected patients to contact their sexual partners, inform them of their risk for infection, and encourage them to seek medical care. A second method, booklet-enhanced partner referral, also provides the patients with booklets that have referral tear-out cards for distribution to sex partners. The new method, known as patient-delivered partner treatment, gives the patient an antibiotic to offer to his partner.

To compare the efficacy of patient-delivered partner treatment with standard and booklet-enhanced partner referral, the researchers enrolled 977 men from an STD clinic in New Orleans. The men had all had a diagnosis of urethritis due to chlamydia and/or gonorrhea infection, and most reported two or more sex partners. The men were each randomly assigned to one of the three partner treatment arms. Nearly 80 percent of the patients completed a follow-up interview four weeks later, and 38 percent were re-tested for STDs.

The researchers found that about 70 percent of men in the patient-delivered partner treatment arm gave the intervention to their partners (giving antibiotics), compared with 58 percent of men in the booklet-enhanced arm (giving tear-out referral cards), and 48 percent of men in the standard p artner referral arm (telling partners to get treated). Men in the patient-delivered partner treatment arm were also less likely than men in either of the other two arms to have unprotected sex before their partners were treated for STDs. Finally, men in the patient-delivered partner treatment and booklet-enhanced arms were far less likely than men in the standard partner referral arm to re-test positive for chlamydia and gonorrhea at follow-up.

Patient-delivered partner treatment is not yet used widely due mainly to fears that are largely unfounded, said Patricia Kissinger, PhD, of Tulane University School of Public Health and Tropical Medicine and lead author of the article. "Clinicians have fears of legal liability, particularly if the partners have side effects. In three randomized trials [on patient-delivered partner treatment] that have been conducted, there have been no reports of adverse events," Dr. Kissinger said. "Particularly for chlamydia, there is little chance of side effects with azithromycin," the antibiotic given to patients in patient-delivered partner treatment.

Another worry that clinicians may have about patient-delivered partner treatment is "that partners will not get treated and counseled for other [STDs] they may have, such as HIV" if they receive treatment for chlamydia or gonorrhea, Dr. Kissinger said. "While this is a valid concern, the alternative to not doing patient-delivered partner treatment is to rely on the patient to refer the partners. We know that that results in less than 50 percent of the partners getting treated. So those partners were probably not going to get those services anyway."

The relative success of patient-delivered partner treatment probably lies in the fact that, with the more traditional methods, patients just had to admit to their partners that there was a problem. With the new method, the patients can offer their partners a solution. "The patients really like the empowerment of being abl e to give the medicine to their partners," Dr. Kissinger said. And if it helps to prevent the spread and recurrence of STDs, patient-delivered partner treatment could be a valuable tool to add to the physician's black bag.


'"/>

Source:


Related biology news :

1. Grand Challenges in Global Health initiative funds Yale project
2. Detecting explosives with honeybees
3. Detecting microalgae in coastal waters
4. Detecting poisons in nectar is an odour-ous task for honeybees
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Jump-starting T Cells In Skin Cancer
7. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
8. Fox Chase Cancer Center scientists identify immune-system mutation
9. Breakthrough Microarray-based Technology for the Study of Cancer
10. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
11. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/15/2016)... Research and Markets has announced ... 2016-2020,"  report to their offering.  , ... global gait biometrics market is expected to grow ... 2016-2020. Gait analysis generates multiple variables ... to compute factors that are not or cannot ...
Breaking Biology News(10 mins):
(Date:5/5/2016)... ... 2016 , ... American Process, Inc. (API) announced that the ... 9,322,133 and 9,322,134, to API and its affiliated companies for BioPlus® nanocellulose technology. ... compositions. In addition to these patents and U.S. Patent No. 9,187,865 awarded ...
(Date:5/4/2016)... ... 05, 2016 , ... CereScan, the nation’s leader in providing ... National Stroke Awareness Month in May. An infographic created by CereScan will ... CereScan will donate $1 up to a maximum of $3,000 through users who ...
(Date:5/4/2016)... , May 4, 2016  Bayer today announced ... compound Stivarga ® (regorafenib) tablets for the ... has met its primary endpoint of a statistically ... RESORCE, evaluated the efficacy and safety of regorafenib ... after treatment with sorafenib. The safety and tolerability ...
(Date:5/4/2016)... Kansas City, Missouri (PRWEB) , ... May 04, 2016 , ... ... President of Professional and Agricultural Sales. , Doug began his career at PBI-Gordon ... has since served in a wide variety of roles, ranging from customer service to ...
Breaking Biology Technology: